ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
Clinical trial NCT04523857 · RECRUITING
Trial details
- NCT number
- NCT04523857
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-01
- Primary completion
- 2027-12-01
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.